Virginia BioTechnology Research Park

The Park and Intelliject Featured on NPR for Sanofi Aventis Deal

 

David R. Lohr, Vice President of Business Development of Virginia BioTechnology Research Park, and Spencer Williamson, CEO of Intelliject, Inc., were featured on NPR on December 1, 2009 to discuss Intelliject’s new deal with sanofi-aventis U.S. and their history with the Park.  Intelliject, Inc. recently announced an exclusive license with sanofi-aventis U.S. for a novel epinephrine auto-injector, in the U.S. and Canada territory. Under the license, sanofi-aventis U.S. will be responsible for manufacturing and commercialization. Intelliject will be responsible for the on-going development and for obtaining U.S. regulatory approval and has retained certain co-promotion rights in the territory.